{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:50:09Z","timestamp":1780357809555,"version":"3.54.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>An open-label, pilot study was conducted to evaluate deferasirox\/deferiprone combination chelation therapy in adult patients with transfusion-dependent thalassemia and severe iron overload. Enrollment proved difficult. Nine patients (median age, 27.4\u2009y; ferritin, 4965\u2009ng\/mL; liver iron concentration, 28.5\u2009mg\/g dry weight; cardiac T2*, 13.3\u2009ms) received treatment. Two were withdrawn for treatment-related adverse effects. Arthralgia (4 patients) and gastrointestinal symptoms (5 patients) were common; no episodes of neutropenia\/agranulocytosis occurred. Adherence difficulties were common. Of 6 patients with 12 to 18 months follow-up, 3 showed improvement in cardiac T2* and 2 in liver iron. Combination oral chelation may be effective but adverse effects and adherence challenges may limit efficacy.<\/jats:p>","DOI":"10.1097\/mph.0000000000001269","type":"journal-article","created":{"date-parts":[[2018,8,5]],"date-time":"2018-08-05T23:20:16Z","timestamp":1533511216000},"page":"e47-e50","source":"Crossref","is-referenced-by-count":12,"title":["Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden"],"prefix":"10.1097","volume":"41","author":[{"given":"John","family":"Hammond","sequence":"first","affiliation":[{"name":"Division of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago"},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Fogel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Children\u2019s Hospital of Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hammond","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene","family":"Kokroko","sequence":"additional","affiliation":[{"name":"Division of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L.","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Division of Hematology"},{"name":"Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy","year":"2015","journal-title":"Eur J Haematol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/pbc.25533","article-title":"The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: a prospective, single center, open-label study","volume":"62","author":"Totadri","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","article-title":"Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance","volume":"105","author":"St. Pierre","year":"2005","journal-title":"Blood"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jmri.10332","article-title":"A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload","volume":"18","author":"Westwood","year":"2003","journal-title":"J Magn Reson Imaging"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/ejh.12241","article-title":"Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count","volume":"92","author":"El-Beshlawy","year":"2014","journal-title":"Eur J Haematol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/pbc.24920","article-title":"Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis","volume":"61","author":"Elalfy","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ajh.24479","article-title":"Deferiprone-induced agranulocytosis: 20 years of clinical observations","volume":"91","author":"Tricta","year":"2016","journal-title":"Am J Hematol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.24668","article-title":"New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II ECLIPSE study","volume":"92","author":"Taher","year":"2017","journal-title":"Am J Hematol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3324\/haematol.2009.014696","article-title":"Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias","volume":"95","author":"Cappellini","year":"2010","journal-title":"Haematologica"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"Br J Haematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:42:50Z","timestamp":1695012170000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201901000-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001269","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}